Potency determination of inactivated H7 influenza vaccines using monoclonal antibody ‐based ELISA and biolayer interferometry assays

ConclusionsThe availability of multiple H7 mAbs, directed to different HA epitopes, provides needed redundancy in the potency analysis as A(H7N9) viruses continue to evolve antigenically, and suggests the importance of having a broad, well‐characterized panel of mAbs available for development of vaccines against influenza strains with pandemic potential. In addition, the results highlight the potential of mAb‐based platform such as ELISA and BLI for development as alternative methods for determining the potency of inactivated influenza vaccines.This article is protected by copyright. All rights reserved.
Source: Influenza and Other Respiratory Viruses - Category: Virology Authors: Tags: Original Article Source Type: research